KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Depreciation & Amortization (CF) (2016 - 2017)

Historic Depreciation & Amortization (CF) for Bio-Rad Laboratories (BIO) over the last 9 years, with Q3 2017 value amounting to $35.4 million.

  • Bio-Rad Laboratories' Depreciation & Amortization (CF) fell 811.94% to $35.4 million in Q3 2017 from the same period last year, while for Jun 2018 it was $35.4 million, marking a year-over-year decrease of 6760.92%. This contributed to the annual value of $131.8 million for FY2015, which is 1207.47% down from last year.
  • As of Q3 2017, Bio-Rad Laboratories' Depreciation & Amortization (CF) stood at $35.4 million, which was down 811.94% from $37.0 million recorded in Q2 2017.
  • Bio-Rad Laboratories' 5-year Depreciation & Amortization (CF) high stood at $42.0 million for Q4 2013, and its period low was $32.1 million during Q2 2015.
  • Over the past 5 years, Bio-Rad Laboratories' median Depreciation & Amortization (CF) value was $35.8 million (recorded in 2014), while the average stood at $35.8 million.
  • As far as peak fluctuations go, Bio-Rad Laboratories' Depreciation & Amortization (CF) skyrocketed by 1831.34% in 2013, and later crashed by 1493.8% in 2015.
  • Over the past 5 years, Bio-Rad Laboratories' Depreciation & Amortization (CF) (Quarter) stood at $42.0 million in 2013, then dropped by 5.35% to $39.8 million in 2014, then decreased by 14.94% to $33.8 million in 2015, then increased by 13.77% to $38.5 million in 2016, then decreased by 8.12% to $35.4 million in 2017.
  • Its Depreciation & Amortization (CF) stands at $35.4 million for Q3 2017, versus $37.0 million for Q2 2017 and $33.7 million for Q1 2017.